Keywords: Merck KGaA, Merck Serono, Newron, Safinamide, ImmuPharma, Lupuzor, Cephalon, Teva, Parkson's disease, Lupus

Merck returns safinamide rights to Newron; ImmuPharma regains Lupuzor from Cephalon

Article | 24 October 2011

Print This

As part of the ongoing review and re-prioritization of its R&D pipeline, biotech firm Merck Serono, a unit ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in